Skip to main content
. 2013 Aug 8;5:215–224. doi: 10.2147/CMAR.S44539

Figure 2.

Figure 2

Cost-effectiveness acceptability curve depicting the expected marginal cost/QALY gained with aprepitant versus the UK clinical practice comparator regimen.

Note: The Y-axis shows the probability of the aprepitant regimen being cost-effective as a function of increasing levels of willingness to pay (shown on X-axis).

Abbreviations: £, pound sterling; QALY, quality-adjusted life year.